Clinical Trial Update: Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial reports results for using 90Y-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen before allogeneic hematopoietic cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED